Senger D R, Claffey K P, Benes J E, Perruzzi C A, Sergiou A P, Detmar M
Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA.
Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13612-7. doi: 10.1073/pnas.94.25.13612.
Vascular endothelial growth factor (VEGF), also known as vascular permeability factor, is a cytokine of central importance for the angiogenesis associated with cancers and other pathologies. Because angiogenesis often involves endothelial cell (EC) migration and proliferation within a collagen-rich extracellular matrix, we investigated the possibility that VEGF promotes neovascularization through regulation of collagen receptor expression. VEGF induced a 5- to 7-fold increase in dermal microvascular EC surface protein expression of two collagen receptors-the alpha1beta1 and alpha2beta1 integrins-through induction of mRNAs encoding the alpha1 and alpha2 subunits. In contrast, VEGF did not induce increased expression of the alpha3beta1 integrin, which also has been implicated in collagen binding. Integrin alpha1-blocking and alpha2-blocking antibodies (Ab) each partially inhibited attachment of microvascular EC to collagen I, and alpha1-blocking Ab also inhibited attachment to collagen IV and laminin-1. Induction of alpha1beta1 and alpha2beta1 expression by VEGF promoted cell spreading on collagen I gels which was abolished by a combination of alpha1-blocking and alpha2-blocking Abs. In vivo, a combination of alpha1-blocking and alpha2-blocking Abs markedly inhibited VEGF-driven angiogenesis; average cross-sectional area of individual new blood vessels was reduced 90% and average total new vascular area was reduced 82% without detectable effects on the pre-existing vasculature. These data indicate that induction of alpha1beta1 and alpha2beta1 expression by EC is an important mechanism by which VEGF promotes angiogenesis and that alpha1beta1 and alpha2beta1 antagonists may prove effective in inhibiting VEGF-driven angiogenesis in cancers and other important pathologies.
血管内皮生长因子(VEGF),也被称为血管通透因子,是一种在与癌症及其他病症相关的血管生成中至关重要的细胞因子。由于血管生成通常涉及内皮细胞(EC)在富含胶原蛋白的细胞外基质内的迁移和增殖,我们研究了VEGF通过调节胶原蛋白受体表达来促进新血管形成的可能性。VEGF通过诱导编码α1和α2亚基的mRNA,使两种胶原蛋白受体——α1β1和α2β1整合素在真皮微血管EC表面蛋白表达增加了5至7倍。相比之下,VEGF并未诱导同样与胶原蛋白结合有关的α3β1整合素表达增加。整合素α1阻断抗体和α2阻断抗体各自部分抑制了微血管EC与I型胶原蛋白的附着,并且α1阻断抗体也抑制了与IV型胶原蛋白和层粘连蛋白-1的附着。VEGF诱导的α1β1和α2β1表达促进了细胞在I型胶原蛋白凝胶上的铺展,而α1阻断抗体和α2阻断抗体的联合使用则消除了这种铺展。在体内,α1阻断抗体和α2阻断抗体的联合使用显著抑制了VEGF驱动的血管生成;单个新生血管的平均横截面积减少了90%,新生血管总面积平均减少了82%,而对已存在的脉管系统没有可检测到的影响。这些数据表明,EC诱导α1β1和α2β1表达是VEGF促进血管生成的重要机制,并且α1β1和α2β1拮抗剂可能在抑制癌症及其他重要病症中VEGF驱动的血管生成方面被证明是有效的。